Rallybio (RLYB) Net Income (2020 - 2026)
Rallybio (RLYB) posted Net Income of -$8.3 million for Q1 2026, down 41.46% sequentially from -$5.9 million in Q4 2025, and up 6.48% YoY from -$7.8 million in Q1 2025.
Rallybio (RLYB) Net Income (2020 - 2026) Analysis & Trends
Rallybio has reported Net Income for 7 years, with the latest figure at -$8.3 million in Q1 2026.
- Quarterly Net Income rose 6.48% year-over-year to -$8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.5 million (up 83.65% YoY) and the FY2025 annual result came in at -$8.1 million, up 85.41% from the prior year.
- Net Income slipped to -$8.3 million in Q1 2026 per RLYB's latest filing, from -$5.9 million in the prior quarter.
- Over five years, Net Income peaked at $16.0 million in Q3 2025 and troughed at -$19.6 million in Q4 2023.
- A 5-year average of -$12.4 million and a median of -$15.7 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income sank 84.88% in 2022, then surged 247.9% in 2025.
- Over 5 years, Net Income stood at -$16.0 million in 2022, then dropped by 22.77% to -$19.6 million in 2023, then soared by 45.93% to -$10.6 million in 2024, then soared by 44.87% to -$5.9 million in 2025, then sank by 41.46% to -$8.3 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$8.3 million, -$5.9 million, and $16.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | 43.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.67 Mn |
| Mar 31, 2026 | -8.28 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | 16.02 Mn |
| Jun 30, 2025 | -9.42 Mn |
| Mar 31, 2025 | -8.85 Mn |
| Dec 31, 2024 | -10.61 Mn |
| Sep 30, 2024 | -10.83 Mn |
| Jun 30, 2024 | -15.75 Mn |
| Mar 31, 2024 | -18.34 Mn |
| Dec 31, 2023 | -19.63 Mn |
| Sep 30, 2023 | -17.73 Mn |
| Jun 30, 2023 | -18.41 Mn |
| Mar 31, 2023 | -16.76 Mn |
| Dec 31, 2022 | -15.99 Mn |
| Sep 30, 2022 | -18.24 Mn |
| Jun 30, 2022 | -17.25 Mn |
| Mar 31, 2022 | -14.11 Mn |
| Dec 31, 2021 | -12.19 Mn |
| Sep 30, 2021 | -9.86 Mn |